This novel monoclonal antibody, Pritoxaximab – formerly known as DXX00601 – presents significant opportunity in the treatment of severe immune condition (TRALI). Developed by scientists, Pritoxaximab functions by https://dirstop.com/story29637805/pritoxaximab-a-deep-dive-into-dxx00601-s-potential